302. Leber hereditary optic neuropathy Clinical trials / Disease details
Clinical trials : 22 / Drugs : 16 - (DrugBank : 4) / Drug target genes : 5 - Drug target pathways : 33
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04912843 (ClinicalTrials.gov) | June 18, 2021 | 13/5/2021 | Gene Therapy Clinical Trial for the Treatment Of Leber's HereDitary Optic Neuropathy Associated With ND4 Mutations | A Phase 1/2/3, Single-arm, Multi-center, Two-stage Clinical Trial to Evaluate the Safety and Efficacy of Gene Therapy for Leber Hereditary Optic Neuropathy (LHON) Associated With ND4 Mutation | Leber Hereditary Optic Neuropathy (LHON) | Drug: NR082 injection | Wuhan Neurophth Biotechnology Limited Company | NULL | Recruiting | 12 Years | 75 Years | All | 55 | Phase 1/Phase 2 | China |